BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52. [PMID: 32066623 DOI: 10.1136/gutjnl-2018-317593] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 37.5] [Reference Citation Analysis]
Number Citing Articles
1 Hill TA, Crooks CJ, West J, Morling JR. Trends in indirect liver function marker testing in Wales from 2000 to 2017 and their association with age and sex: an observational study. BMJ Open Gastroenterol 2022;9:e000885. [PMID: 35487590 DOI: 10.1136/bmjgast-2022-000885] [Reference Citation Analysis]
2 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Reference Citation Analysis]
3 Loomba R. MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis. Hepatology 2021;73:881-3. [PMID: 33179266 DOI: 10.1002/hep.31624] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
4 Subhani M, Knight H, Ryder S, Morling JR. Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis. Alcohol and Alcoholism 2021;56:185-200. [DOI: 10.1093/alcalc/agaa143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. Int J Mol Sci 2020;22:E40. [PMID: 33375190 DOI: 10.3390/ijms22010040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
7 Fujii H, Enomoto M, Fukumoto S, Kimura T, Nadatani Y, Takashima S, Hagihara A, Uchida-Kobayashi S, Tamori A, Nishimoto N, Kawada N. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open 2021;5:801-8. [PMID: 34263075 DOI: 10.1002/jgh3.12590] [Reference Citation Analysis]
8 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
9 Ciardullo S, Bianconi E, Zerbini F, Perseghin G. Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. Diabetes Res Clin Pract 2021;177:108879. [PMID: 34058299 DOI: 10.1016/j.diabres.2021.108879] [Reference Citation Analysis]
10 Czajka P, Przybyłkowski A, Nowak A, Postula M, Wolska M, Mirowska-Guzel D, Czlonkowska A, Eyileten C. Antiplatelet drugs and liver fibrosis. Platelets 2021;:1-10. [PMID: 33577391 DOI: 10.1080/09537104.2021.1883574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ciardullo S, Cannistraci R, Mazzetti S, Mortara A, Perseghin G. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. Front Endocrinol (Lausanne) 2021;12:711484. [PMID: 34381424 DOI: 10.3389/fendo.2021.711484] [Reference Citation Analysis]
12 Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Reference Citation Analysis]
13 Peltekian KM. For fatty liver diseases, it is time to utilize non-invasive fibrosis tests to predict liver related events rather than just histological stages of hepatic fibrosis! Ann Hepatol 2020;19:583-4. [PMID: 32853777 DOI: 10.1016/j.aohep.2020.07.011] [Reference Citation Analysis]
14 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
15 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Hari A. Ultrasound Elastography-Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment. Medicina (Kaunas) 2021;57:516. [PMID: 34064124 DOI: 10.3390/medicina57060516] [Reference Citation Analysis]
17 Wan S, Huang C, Wang A, Zhu X. Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ 2020;8:e9050. [PMID: 32355580 DOI: 10.7717/peerj.9050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
19 Cardoso AC, A Villela-Nogueira C, de Figueiredo-Mendes C, Leão Filho H, Pinto Silva RA, Valle Tovo C, Perazzo H, Matteoni AC, de Carvalho-Filho RJ, Lisboa Bittencourt P. Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. Ann Hepatol 2021;22:100341. [PMID: 33737252 DOI: 10.1016/j.aohep.2021.100341] [Reference Citation Analysis]
20 Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology 2021:S0016-5085(21)03795-1. [PMID: 34822801 DOI: 10.1053/j.gastro.2021.10.051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
21 Anugwom C, Campbell C, Debes JD. Assessment of subclinical effects of Hepatitis E virus infection in the United States. J Viral Hepat 2021;28:1091-7. [PMID: 33894038 DOI: 10.1111/jvh.13519] [Reference Citation Analysis]
22 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
23 Mulroy E, Baschieri F, Magrinelli F, Latorre A, Cortelli P, Bhatia KP. Movement Disorders and Liver Disease. Mov Disord Clin Pract 2021;8:828-42. [PMID: 34401403 DOI: 10.1002/mdc3.13238] [Reference Citation Analysis]
24 Jang W, Jo S, Song JS, Hwang HP, Kim SH. Comparison of diffusion-weighted imaging and MR elastography in staging liver fibrosis: a meta-analysis. Abdom Radiol (NY) 2021;46:3889-907. [PMID: 33770223 DOI: 10.1007/s00261-021-03055-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li XH, Huang R, Yang M, Wang J, Gao YH, Jin Q, Ma DL, Wei L, Rao HY. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral. World J Gastroenterol 2022; 28(20): 2214-2226 [DOI: 10.3748/wjg.v28.i20.2214] [Reference Citation Analysis]
26 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
27 Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-88. [PMID: 34923653 DOI: 10.1002/hep.32285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
28 Vitale DL, Icardi A, Rosales P, Spinelli FM, Sevic I, Alaniz LD. Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy. Front Oncol 2021;11:710061. [PMID: 34676159 DOI: 10.3389/fonc.2021.710061] [Reference Citation Analysis]
29 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2022;71:156-62. [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 43.0] [Reference Citation Analysis]
30 Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology 2022;75:661-72. [PMID: 34496054 DOI: 10.1002/hep.32145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
31 Habash NW, Sehrawat TS, Shah VH, Cao S. Epigenetics of Alcohol-Related Liver Diseases. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100466] [Reference Citation Analysis]
32 Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology 2021;73:1194-8. [PMID: 32544255 DOI: 10.1002/hep.31420] [Cited by in Crossref: 113] [Cited by in F6Publishing: 86] [Article Influence: 113.0] [Reference Citation Analysis]
33 Neuberger J, Cain O. The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics. Hepat Med 2021;13:59-69. [PMID: 34163263 DOI: 10.2147/HMER.S278076] [Reference Citation Analysis]
34 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
35 [DOI: 10.7759/cureus.24676] [Reference Citation Analysis]
36 Vuppalanchi R, Loomba R. Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box. Hepatology 2021;73:2095-8. [PMID: 33545738 DOI: 10.1002/hep.31734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study. Clin Res Hepatol Gastroenterol 2021;45:101754. [PMID: 34303827 DOI: 10.1016/j.clinre.2021.101754] [Reference Citation Analysis]
38 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
39 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
40 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
41 Lyu H, Tang H, Liang Y, Huang S, Wang Y, Huang W, Zhou Y. Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:841314. [DOI: 10.3389/fimmu.2022.841314] [Reference Citation Analysis]
42 Natarajan Y, Loomba R. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. Journal of Clinical and Experimental Hepatology 2022;12:174-9. [DOI: 10.1016/j.jceh.2021.08.002] [Reference Citation Analysis]
43 Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, Largura A, Arrese M, Oliveira CP. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100253. [PMID: 32949785 DOI: 10.1016/j.aohep.2020.08.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Hui WZ, Sook Yee NT, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01280-5. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Reference Citation Analysis]
45 Zhang C, Zhang C. Analysis of current status of quantitative detection of biomarkers for liver fibrosis in Clinical labs in China. J Clin Lab Anal 2022;:e24490. [PMID: 35587485 DOI: 10.1002/jcla.24490] [Reference Citation Analysis]
46 Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
47 Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2021;14:17562848211050436. [PMID: 34646360 DOI: 10.1177/17562848211050436] [Reference Citation Analysis]
48 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhou YJ, Wong VW, Zheng MH. Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need. Hepatobiliary Surg Nutr 2021;10:388-90. [PMID: 34159171 DOI: 10.21037/hbsn-21-80] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Besutti G, Bonilauri L, Manicardi E, Venturelli F, Bonelli E, Monelli F, Manicardi V, Valenti L, Ligabue G, Schianchi S, Massari M, Riva N, Froio E, Tagliavini E, Pattacini P, Giorgi Rossi P. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Res Clin Pract 2021;177:108882. [PMID: 34082056 DOI: 10.1016/j.diabres.2021.108882] [Reference Citation Analysis]
51 Jiang H, Fowler KJ, Bashir MR. The Varied Modalities of Liver Elastography and How Each Fits Into a Hepatology Practice. Clin Liver Dis (Hoboken) 2021;17:326-9. [PMID: 33968398 DOI: 10.1002/cld.1099] [Reference Citation Analysis]
52 Lonardo A. Metabolomic signature: one step forward in the process of obtaining NAFLD patients' metabolic identity card. Am J Clin Nutr 2022;115:603-5. [PMID: 35134121 DOI: 10.1093/ajcn/nqab399] [Reference Citation Analysis]
53 Patel D, Shan A, Mathews S, Sathe M. Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management. Nutrients 2022;14:1028. [PMID: 35268004 DOI: 10.3390/nu14051028] [Reference Citation Analysis]
54 Yao Y, Ni H, Wang X, Xu Q, Zhang J, Jiang L, Wang B, Song S, Zhu X. A New Biomarker of Fecal Bacteria for Non-Invasive Diagnosis of Colorectal Cancer. Front Cell Infect Microbiol 2021;11:744049. [PMID: 34976850 DOI: 10.3389/fcimb.2021.744049] [Reference Citation Analysis]
55 Geier A, Boursier J. Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts? Gut 2020;69:1164-5. [PMID: 32220903 DOI: 10.1136/gutjnl-2020-320785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
56 Zhang XQ, Zeng J, Jin JY, Wang JF, Chi YY, Zheng RQ. Shear-Wave Dispersion Slope of the Liver: Effect of Study Protocol and Ascites on the Measurement Applicability. Ultrasound Med Biol 2022;48:59-67. [PMID: 34702641 DOI: 10.1016/j.ultrasmedbio.2021.09.012] [Reference Citation Analysis]
57 Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med 2021;41:16-24. [PMID: 32829576 DOI: 10.3343/alm.2021.41.1.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Tamai H, Okamura J, Ohoshi T, Wakasaki H. Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis. Healthcare (Basel) 2021;9:523. [PMID: 33946842 DOI: 10.3390/healthcare9050523] [Reference Citation Analysis]
59 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 2021. [PMID: 34927277 DOI: 10.1111/apt.16745] [Reference Citation Analysis]
60 Subhani M, Sheth A, Ahmad B, Ryder S. How to interpret and manage abnormal liver blood test results in older people. Br J Hosp Med (Lond) 2021;82:1-8. [PMID: 34431345 DOI: 10.12968/hmed.2021.0114] [Reference Citation Analysis]
61 Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]
62 Mantha A, Lee RO Jr, Wolfson AM. Patient selection for heart transplant: balancing risk. Curr Opin Organ Transplant 2022;27:36-44. [PMID: 34939963 DOI: 10.1097/MOT.0000000000000943] [Reference Citation Analysis]
63 Liu JY, Ding ZY, Zhou ZY, Dai SZ, Zhang J, Li H, Du Q, Cai YY, Shang QL, Luo YH, Xiao EH. Multiparameter magnetic resonance imaging of liver fibrosis in a bile duct ligation mouse model. World J Gastroenterol 2021; 27(47): 8156-8165 [DOI: 10.3748/wjg.v27.i47.8156] [Reference Citation Analysis]